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 Abstract 
 Clinically, Alzheimer’s disease (AD) is by far the most common cause of dementia. Criteria for the 
diagnosis of dementia with Lewy bodies (DLB) are highly specific but not at all sensitive, which 
is reflected by the higher number of DLB cases detected histopathologically at autopsy. Imag-
ing of dopamine transporter with FP-CIT SPECT is one possibility to increase sensitivity. Patho-
logical confirmation was also included in the revised consensus criteria for the diagnosis of DLB. 
However, in the absence of parkinsonism, one of the core features, a clinical diagnosis of AD is 
more likely. The role of FP-CIT SPECT in DLB diagnosis remains to be clarified. Based on our 3 
case reports and a review of the literature, the utility of this imaging method in the differential 
diagnosis of AD and DLB is highlighted.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  In postmortem studies, dementia with Lewy bodies (DLB) accounts for 10–20% of all 
cases of dementia and can therefore be regarded as the second most common cause of de-
mentia after Alzheimer’s disease (AD)   [1–3]  . For a definite diagnosis, autopsy is required. 
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However, confirmation of the diagnosis during the patient’s lifetime is both reasonable and 
important, since patients with DLB respond to acetylcholine esterase inhibitors   [4]   and fur-
thermore demonstrate a hypersensitivity to antipsychotic treatment   [5, 6]  . Clinical consen-
sus criteria from 1996 possess a fairly high specificity with 80–90%   [7]  , but only a low sensi-
tivity, decreasing to 30% according to some studies   [8–10]  . DLB is most commonly misdiag-
nosed as AD  [10, 11] . An improvement in clinical accuracy – particularly when AD is part of 
the differential diagnosis – seems to be worthwhile. 
    In postmortem studies, a 57–90% loss of presynaptic dopamine transporters could be 
demonstrated in DLB but not in AD   [12, 13]  . The presence a dopaminergic abnormality in 
DLB including striatal dopaminergic transporter loss was outlined in vivo with positron 
(PET)   [14]   and single-photon emission computed tomography (SPECT)   [15, 16]  . On the 
grounds of these observations, a positive, i.e. abnormal, FP-CIT-SPECT was included as a 
feature suggestive of DLB in the revised clinical consensus criteria from 2005   [17]  . Sensitiv-
ity could thereby be increased up to 81.3%   [18, 19]  . Moreover, in a follow-up study over a 
period of 1 year, it was shown that in case of clinical suspicion, an FP-CIT scan may be help-
ful. Of 19 patients initially diagnosed as having possible and after 1 year as having probable 
DLB, 12 patients (63.2%) had pathological FP-CIT-SPECT, while the remaining 7 cases that 
were assessed as non-DLB at the 1-year follow-up had normal DaTSCAN (100% specificity) 
 [19] .
    Another challenge in differential diagnosis resides in the distinction between Parkin-
son’s disease and dementia (PDD). It is still an open question whether the underlying neu-
robiological changes result from one and the same mechanism in both entities. FP-CIT-
SPECT is abnormal in both DLB and PDD   [20, 21]  , possibly with a lower dopamine trans-
porter uptake in PDD than in DLB  [18] . Regarding the current clinical criteria, an agreement 
was reached that the diagnosis of DLB is not possible when extrapyramidal features are pres-
ent for   1  12 months before the diagnosis of dementia   [17]  . In the following, we describe 3 
cases who had no extrapyramidal signs, and thus DLB was the only possible diagnosis (  ta-
ble 1  ). Basic demographic data are listed in   table 2  .
Dementia Parkinsonism Fluctuations Visual 
hallucinations
Case 1 + – + –
Case 2 + – – +
Case 3 + – (+) (+)
Case 1 Case 2 Case 3
Age, years 80 82 72
Gender male male male
Clinical symptom duration, years 2 1  1 
MMSE 28 24 26
Phosphorylated tau, pg/ml 107 62 –
Tau, pg/ml 404 408 –
A1–42, pg/ml 469 577 –
Table 1.   Presence of core 
symptoms of DLB in the 3 cases
Table 2.   Basic demographic data 
for the 3 cases285
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  C a s e   1  
  An 80-year-old male complained of progressively decreasing memory over the previous 
2 years. Word finding was particularly difficult. Orientation in time and place was reduced, 
and he developed difficulties in finding the treatment rooms during hospitalization. Addi-
tionally, vision began to be disturbed. He scarcely read anymore due to the effort required. 
Financial affairs were managed together with his wife. Neurological examination was com-
pletely normal, and, in particular, there were no signs of rigidity, hypokinesia or tremor. The 
UPDRS-III motor score was 0. Clinical chemistry did not reveal any significant abnormality 
apart from slightly elevated homocysteine (16.1     mol/l). Mini Mental State Examination 
(MMSE) was within normal limits (28 of 30 points), but extensive neuropsychological testing 
revealed significant abnormalities regarding attention, visuospatial capabilities, short-term 
and working verbal memory, verbal episodic memory and naming. Orientation and executive 
functions were preserved (  table 3  ). Moreover, during the session massive fluctuations were 
present. Cerebrospinal fluid (CSF) was normal with respect to basic parameters, but phos-
phorylated tau at threonine 231 was elevated and   -amyloid (A   1–42 ) was decreased. Cerebral 
magnetic resonance imaging (MRI) revealed no significant vascular lesions, but frontotem-
poral atrophy was noted, with relative preservation of hippocampal formation (  fig. 1  ).
Case 1 Case 2 Case 3
MMSE 28 24 26
Attention ff
Visuoconstruction fff
Episodic memory fff
Short-term/working memory ff
Naming ff}
Executive function } ff
Orientation }}}
f   = 1.5 SD below the median of a control sample (according to the 
respective test manuals); } = value within the normal range of con-
trols.
Table 3.   Neuropsychological 
profiles of the 3 cases 
  Fig. 1.   cMRI of the 3 cases (T  2  , coronal plane, including hippocampal area). 286
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  According to DSM IV  [22]  criteria, dementia was diagnosed and according to NINCDS-
ADRDA criteria  [23]  probable dementia of the Alzheimer type was assumed: symptoms were 
progressive and were demonstrated in more than one cognitive domain. The findings were 
supported by typical CSF data. Although only one core feature (fluctuation) was present, FP-
CIT-SPECT was performed and revealed a diminished dopamine transporter uptake in the 
basal ganglia (  fig. 2  a). In conclusion, following the revised consensus criteria for DLB from 
2005, probable DLB was diagnosed.
  C a s e   2  
 An 82-year-old male with AD diagnosed 1 year previously was admitted to the inpatient 
neurological department due to uncontrolled visual hallucinations. On neurological exami-
nation, there were no abnormalities, particularly no extrapyramidal signs. UPDRS-III motor 
score was 0. No fluctuations were observed or reported. In neuropsychology, MMSE was 
only slightly decreased (24 of 30 points), but apart from orientation all other cognitive do-
  Fig. 2.    a   Heterogeneous decrease in stria-
tal dopamine transporters, indirectly indi-
cating the too high uptake of   123 I-FP-CIT 
(DaTSCAN) in the background.   b   De-
creased uptake of   123 I-FP-CIT  (DaTSCAN) 
in  b o th  p u tamin a  an d  n o rm al  u p tak e  in  
both caudate nuclei.   c   Uptake of   123 I-FP-
CIT (DaTSCAN) is almost absent in both 
putamina (accentuated on the left side) and 
normal in both caudate nuclei. 287
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mains were at least 1.5 SD from age-corrected means (attention, executive function, verbal 
short-term, working and episodic memory, naming and visuoconstruction;   table 3  ). MRI of 
the head revealed global atrophy including the mesiotemporal region (  fig. 1  ). CSF analysis 
was normal (including tau and A    1–42  ). Due to the neuropsychological findings and at least 
one core feature of DLB, a DaTSCAN was performed and bilateral diminished dopamine 
transporter uptake was found (  fig. 2  b). On the basis of all the findings, a diagnosis of prob-
able DLB was made.
  C a s e   3  
  A 72-year-old male was admitted to the neurology outpatient clinic with subjective 
memory complaints. He had difficulty in remembering names and terms and moreover ex-
perienced spatial disorientation. Finally, completion of planned actions, e.g. handling of the 
coffee machine, were reported to be impaired. Neurological examination showed no abnor-
mality, in particular no extrapyramidal signs. UPDRS-III motor score was 0. Only upon 
further inquiry, he admitted fluctuations and to some degree visual hallucinations although 
the latter more resembled misperception, were only of short duration and were not very well 
formed. Neuropsychologically, MMSE was almost within the normal range with 26 of 30 
points, but deficits were found in visuospatial capabilities, executive function and verbal 
episodic memory, while orientation and naming were spared. Thorough assessment of atten-
tion was not performed (  table 3  ). MRI of the head revealed some global atrophy but the me-
siotemporal region, including the hippocampus, was spared (  fig. 1  ). No CSF was obtained 
from this patient. DaTSCAN was performed and again dopamine transporter uptake was 
diminished (  fig. 2  c). A diagnosis of probable DLB was made.
Discussion
    To be able to offer optimal therapeutic treatment, an accurate diagnosis during a pa-
tient’s lifetime is important since DLB patients respond to therapy with acetylcholine ester-
ase inhibitors   [6, 24]  . In addition, in DLB patients the sensitivity to antipsychotics is in-
creased, with a 2- to 3-fold increase in mortality   [5]  . Treatment with these drugs has to be 
rational and should be restricted to carefully selected substances. Although the clinical di-
agnosis offers a high specificity, sensitivity with respect to DLB is only very low, leading to 
an important role of supplemental imaging techniques. In particular, distinguishing DLB 
from AD and PD is important.
    Differentiating between DLB and PDD does not require further investigation since they 
are distinguished by an anamnestic criterion: whether or not dementia has developed with-
in 1 year of onset of extrapyramidal signs. Dementia onset during that period suggests a di-
agnosis of DLB, whereas a later onset of dementia is suggestive of PDD.
    Differentiation between DLB and AD is less clear. Since there is a huge overlap of clini-
cal criteria, distinction is not feasible in most cases. Additional diagnostic parameters are 
inappropriate. Results from biomarkers gained by lumbar puncture are very similar in both 
diseases. The increase in tau and phosphorylated tau and decrease in A    1–42   sometimes 
found in AD is less pronounced in DLB  [25, 26] . However in a single case, distinction cannot 
be made. On MRI, mesiotemporal structures seem to be more affected in AD, whereas in 
DLB mesencephalic regions are atrophied  [27] . Again an evaluation of a single subject is very 
difficult. Another imaging technique, perfusion scintigraphy of the brain with   99m Tc-bicisate 
(Neurolite), has been investigated for its possible role as a diagnostic tool. The patterns of 288
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hypoperfusion slightly deviate between DLB and AD, with more occipital involvement in 
DLB, while in AD the characteristic finding is a temporoparietal hypoperfusion  [28–36] , but 
differences are not sufficient  [37]  or at least inferior to those found using FP-CIT-SPECT  [38] . 
Hence depiction of the dopaminergic system using ligands such as FP-CIT offers the greatest 
potential for accurate diagnosis during a patient’s lifetime. Neuroimaging is well tolerated by 
patients, particularly in early stages of the disease. Furthermore, SPECT is readily available, 
analysis is easily adapted to the diagnosis of DLB, and the procedure is not too time consum-
ing. Reduction in FP-CIT is clearly and evidently associated with a fundamental neurobio-
logical alteration recognized in DLB, namely dopaminergic loss   [12, 13]  . The above-men-
tioned reasons explain the increased implementation of FP-CIT-SPECT in routine diagnos-
tics to support a diagnosis of DLB.
  The question of the utility of the FP-CIT-SPECT in the distinction between DLB and AD 
then arises, especially for an early diagnosis. In AD, extrapyramidal signs occur in 20–30%, 
usually later in the course of the disease. Parkinsonism in early stages of dementia therefore 
argues against AD and favors DLB. Thus, whether there are extrapyramidal signs or not has 
a substantial impact on the diagnosis made. Although parkinsonism is one of the core fea-
tures of DLB and occurs frequently in the course of the disease, in up to 75–80% of cases  [39, 
40]   it is not required for a probable diagnosis of DLB. In a review of histopathologically con-
firmed cases from a brain bank and the current literature, parkinsonism was only found as 
a first sign of DLB in about 50% of the 239 study patients   [41, 42]  .
    It remains to be clarified how often an FP-CIT-SPECT will be abnormal in the absence 
of parkinsonism, and what criteria should be met before a DaTSCAN is performed in case 
extrapyramidal signs are absent. Our 3 case reports indicate that a FP-CIT scan may indeed 
be abnormal in the absence of extrapyramidal signs. An overview of the current literature is 
difficult because in most of the cases there are no detailed clinical descriptions of the patients 
and their association with DaTSCAN findings. From the literature, an abnormal DaTSCAN 
was obtained in 6 of 7 cases when parkinsonism was absent  [18, 43, 44] . Furthermore, an ab-
normal DaTSCAN was found in the presence of only minor motoric abnormalities in 7–8 of 
11 patients (UPDRS   !   15) in a further study   [45]  . In the light of these observations, it is in-
teresting that even when extrapyramidal motor signs are present, an abnormal FP-CIT-
SPECT is rarely found in AD   [18, 46] , possibly pointing to an extrastriatal mechanism in the 
development of parkinsonism in AD.
  Conclusion 
  We conclude that to increase diagnostic accuracy FP-CIT-SPECT should be readily 
available once the criteria of possible DLB are met. As demonstrated in our cases, attention 
should be focused on neuropsychological findings, namely preserved orientation, fluctuat-
ing levels of attention and visuoconstructive deficits. The latter two have been shown to be 
sensitive to and predictive of DLB even in the early stages of mild cognitive impairment 
 [47] .
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